μννλ
**μννλ(Sufentanil)**μ λ§€μ° κ°λ ₯ν ν©μ± μ€νΌμ€μ΄λ μ§ν΅μ μ λλ€(ννλμ μ½ 5~10λ°°, λͺ¨λ₯΄νμ 500~1000λ°° μκ°). μμνμμλ μ£Όλ‘ **λ§μ·¨ 보쑰μ ** λλ **κ²½λ§μΈ μ§ν΅μ **λ‘ μ¬μ©λ©λλ€. μ£Όμ μμ ν¬μΈνΈ: * **ν¨λ₯:** λ€λ₯Έ λ§μ λ§μ·¨μ μ λΉν΄ κΉμ μ§ν΅ ν¨κ³Όμ μ°μν μ¬νκ΄κ³ μμ μ±μ μ 곡ν©λλ€. * **λ°ν λ° ν볡:** μμ© λ°νμ΄ λΉ λ₯΄κ³ (1~3λΆ), ννλλ³΄λ€ ν볡 μκ°μ΄ λ λΉ λ¦ λλ€. * **μνμ±:** μ©λ μμ‘΄μ μΈ νΈν‘ λ° μ€μΆμ κ²½κ³ μ΅μ μ μ¬κ°ν μνμ΄ μμΌλ―λ‘ νμμ λν μ§μμ μΈ λͺ¨λν°λ§μ΄ νμμ μ λλ€.
μμ© κΈ°μ : Sufentanil acts as a highly selective and potent **mu-opioid receptor (MOR)** agonist in the central nervous system. * Binding to the G-protein coupled mu-receptor β inhibits adenylate cyclase β decreases intracellular cAMP. * This leads to the opening of inward-rectifying potassium channels (causing hyperpolarization) and the closing of voltage-gated calcium channels. * Result β **decreased release of nociceptive neurotransmitters** (such as Substance P and glutamate), interrupting pain transmission pathways in the dorsal horn of the spinal cord and altering pain perception in the brain.
λλ¬Ό μ’ λ³ μ©λ
- Acute pain relief in an emergency Β· 0.1-0.5 micrograms/kg IV ; constant rate infusion of 0.5-1 micrograms/kg/hour Β· IV Β· CRI
- As a pre-med Β· 3 micrograms/kg IV Β· IV Β· Single dose Β· As a combination for induction: Sufentanil 3 micrograms/kg IV first, then diazepam or midazolam 0.2-0.5 mg IV.
- For epidural analgesia Β· 0.7-1 micrograms/kg diluted to a volume of 0.26 mL/kg with sterile saline Β· Epidural Β· Single dose Β· 1-4 hours Β· Onset of action in 10-15 minutes.
- Acute pain relief in an emergency Β· 0.75-2 micrograms/kg IV ; constant rate infusion of 1-2 micrograms/kg/hour Β· IV Β· CRI
- For surgical pain Β· 5 micrograms/kg IV prior to a CRI. CRI (post-operative) of 0.1 micrograms/kg/hour Β· IV Β· CRI Β· 2-6 hours Β· Duration of effect: 2-6 hours.
μ©λμ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μ°Έκ³ μλ£μ λλ€. νμ μ΅μ λΌλ²¨κ³Ό κ°λ³ νμμ λν΄ νμΈνμμμ€.
ν¬μ¬ κ²½λ‘
κΈκΈ°
- Hypersensitivity to sufentanil or other opioids
μ΄μλ°μ
- Respiratory depression (dose-related)
- CNS depression
- Bradycardia
- Skeletal muscle rigidity
- Asystole (rare)
- Hypercarbia (rare)
- Hypersensitivity reactions (rare)
μ½λ¬Ό μνΈμμ©
- Beta-adrenergic blockers Β· May increase bradycardia and hypotension
- Calcium-channel blockers Β· May increase bradycardia and hypotension
- CNS depressants (e.g., barbiturates) Β· Additive effects can occur, exacerbating CNS or respiratory depression
- Nitrous oxide Β· Can cause cardiovascular depression if used with high dose sufentanil
λͺ¨λν°λ§
- Anesthetic and/or analgesic efficacy
- Cardiac rate
- Respiratory rate
- Pulse oximetry or other methods to measure blood oxygenation
κ³Όμ©λ
In dogs, the LD50 of intravenous sufentanil is 10.1-19.5 mg/kg. **Clinical Signs of Severe Overdose:** * Apnea * Circulatory collapse * Pulmonary edema * Seizures * Cardiac arrest and death **Treatment:** Consists of a combination of supportive therapy (ventilation, cardiovascular support) and administration of an opiate antagonist such as **naloxone**. Although sufentanil has a fairly rapid half-life, multiple doses of naloxone may be necessary. > **Clinical Pearl:** Because of the drug's extreme potency, use a tuberculin syringe to measure dosages less than 1 mL, and employ a dosage calculation/measurement double-check system.
VetSheet μ½λ¬Ό λ νΌλ°μ€λ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μμ¬κ²°μ 보쑰 λꡬμ΄λ©°, μ λ¬Έμ νλ¨μ΄λ μ μ‘°μ¬μ μ΅μ λΌλ²¨μ λμ νμ§ μμ΅λλ€.